AMH Levels Change During Treatment With GnRh Agonist

NACompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Uterine FibroidsEndometriosisEndometriosis of UterusPelvic Pain
Interventions
DRUG

GnRH analogue

"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."

Trial Locations (1)

88100

Chair of Obstetrics and Gynecology - University division - UMG, Catanzaro

All Listed Sponsors
lead

University Magna Graecia

OTHER

NCT02086279 - AMH Levels Change During Treatment With GnRh Agonist | Biotech Hunter | Biotech Hunter